Trafermin for stroke recovery: Is it time for another randomized clinical trial?

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1533-1541

  Paciaroni, Maurizio ^a,b   Bogousslavsky, Julien ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Division of Cardiovascular Medicine   (Italy)

^c Swiss Medical Network   (Switzerland)

Author keywords

Basic fibroblast growth factor; Neuroprotection; Stroke therapy; Trafermin

Indexed keywords

CALCIUM CHANNEL; CITICOLINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; GLUTAMIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 1; INTERLEUKIN 8; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROMODULIN; NITRIC OXIDE; POTASSIUM CHANNEL; RADIOISOTOPE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; TRAFERMIN IODINE 125; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE DISEASE; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CONTINUOUS INFUSION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEVER; HUMAN; HYPOKALEMIA; HYPOTENSION; IMMUNOREACTIVITY; LEUKOCYTOSIS; MORTALITY; NAUSEA; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM CURRENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; SYNAPSE; TREATMENT OUTCOME; VOMITING;

ANIMALS; BRAIN ISCHEMIA; EVIDENCE-BASED MEDICINE; FIBROBLAST GROWTH FACTORS; HUMANS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; EQUUS ASINUS;

EID: 80053641618     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.616888     Document Type: Article

References (79)

1. Lo E, Dalkara T, Moskowitz M. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4:399-415 (Pubitemid 37280178)
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
3. Hacke W, Kaste M, Bluhmki E, et al. for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
4. Fisher M. The ischemic penumbra: a new opportunity for neuroprotection. Cerebrovasc Dis 2006;21(Suppl 2):64-70
5. Hossman KA. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 2006;26:1055-81
6. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49(5 Suppl 4):S66-9 (Pubitemid 27495612)
7. Lees KR, Asplund K, Carolei A, et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 2000;355:1949-54 (Pubitemid 30326099)
8. Diener HC, Cortens M, Ford G, et al. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10 mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-51
9. Clark WM, Williams BJ, Selzer KA, et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999;30:2592-7
10. Bath PMW, Blecic S, Bogousslavsky J, et al. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 2000;31:2257-65
11. Shuaib A, Lees KR, Lyden P, et al. SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71 (Pubitemid 47236281)
12. DeGraba TJ. The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy. Neurology 1998;51(3 Suppl 3):S62-8
13. Wahlgren NG, Ranasinha KW, Rosolacci T, et al. Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1,360 acute stroke patients. Stroke 1999;30:21-8 (Pubitemid 29029436)
14. Fisher M. New approaches to neuroprotective drug development. Stroke 2011;42(1 Suppl):S24-7
15. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974;249:123-7
16. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem 1975;250:2515-20
17. Robson MC, Phillips LG, Lawrence WT, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992;216:401-6; discussion 406-8
18. Tanaka E, Ase K, Okuda T, et al. Mechanism of acceleration of wound healing by basic fibroblast growth factor in genetically diabetic mice. Biol Pharm Bull 1996;19:1141-8 (Pubitemid 26342254)
19. Fisher M, Meadows ME, Do T, et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995;15:953-9
20. Tanaka R, Miyasaka Y, Yada K, et al. Basic fibroblast growth factor increases regional cerebral blood flow and reduces infarct size after experimental ischemia in a rat model. Stroke 1995;26:2154-8; discussion 2158-9
21. Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ Res 1996;79:62-9 (Pubitemid 26196318)
22. Lazarous DF, Scheinowitz M, Shou M, et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995;91:145-53
23. Lanfranconi S, Locatelli F, Corti S, et al. Growth factors in ischemic stroke. J Cell Mol Med 2011;15:1645-87
24. Guo H, Huang L, Cheng M, et al. Serial measurement of serum basic fibroblast growth factor in patients with acute cerebral infarction. Neurosci Lett 2006;39:56-9 (Pubitemid 41739653)
25. Lin DA, Finklestein SP. Basic fibroblast growth factor: a treatment for stroke? Neuroscientist 1997;3:247-50 (Pubitemid 127532812)
26. Issa R, AlQteishat A, Mitsios N, et al. Expression of basic fibroblast growth factor mRNA and protein in the human brain following ischemic stroke. Angiogenesis 2005;8:53-62 (Pubitemid 41223839)
27. Wada K, Sugimori H, Bhide PG, et al. Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats. Stroke 2003;34:2722-8 (Pubitemid 37392774)
28. Maric D, Fiorio Pla A, Chang YH, Barker JL. Self-renewing and differentiating properties of cortical neural stem cells are selectively regulated by basic fibroblast growth factor (FGF) signalling via specific FGF receptors. J Neurosci 2007;27:1836-52
29. Jin-qiao S, Bin S, Wen-hao Z, Yi Y. Basic fibroblast growth factor stimulates the proliferation and differentiation of neural stem cells in neonatal rats after ischemic brain injury. Brain Dev 2009;31:331-40
30. Rose K, Kriha D, Pallast S, et al. Basic fibroblast growth factor: lysine 134 is essential for its neuroprotective activity. Neurochem Int 2007;51:25-31 (Pubitemid 47002044)
31. Zechel S, Werner S, Unsicker K, et al. Expression and functions of fibroblast growth factor 2 (FGF-2) in hippocampal formation. Neuroscientist 2010;16:357-73
32. Kume T, Kouchiyama H, Kaneko S, et al. BDNF prevents NO mediated glutamate cytotoxicity in cultured cortical neurons. Brain Res 1997;756:200-4 (Pubitemid 27241627)
33. Marini AM, Rabin SJ, Lipsky RH, Mocchetti I. Activity-dependent stimulation of TrkB receptors underlies the neuroprotective effect of N-methyl-D-aspartate. Soc Neurosci Abstr 1997;23:650
34. Peterson DA, Lucidi-Philippi CA, Murphy DP, et al. FGF-2 protects entorhinal cortex layer II glutamatergic neurons from axotomy-induced death. J Neurosci 1996;16:886-98 (Pubitemid 26140844)
35. Mattson MP, Murrain M, Guthrie PB, Kater SB. FGF and glutamate: opposing roles in the generation and degeneration of hippocampal neuroarchitecture. J Neurosci 1989;9:3728-32
36. Brandoli C, Sanna A, De Bernardi M, et al. Brain-derived neurotrophic factor and bFGF downregulate NMDA receptor function in cerebellar granule cells. J Neurosci 1998;18:7953-61 (Pubitemid 28441033)
37. 2+ dependent inactivation of NMDA receptor currents in hippocampal neurons. J Neurophysiol 1999;82:3367-77 (Pubitemid 30017461)
38. Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation 1997;96:4083-94
39. Imagami T, Naruse M, Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol 1995;57:171-89
40. Nilius B, Viana F, Droogmans G. Ion channels in vascular endothelium. Annu Rev Physiol 1997;59:145-70 (Pubitemid 27142437)
41. Scharbrodt W, Kuhlmann CRW, Wu Y, et al. Basic FGF-induced endothelial proliferation and NO synthesis involves inward rectifier K+ current. Arterioscler Thromb Vasc Biol 2004;24:1229-33 (Pubitemid 38880013)
42. 2+-activated K+ channels inhibits bFGF-induced proliferation of human endothelial cells. J Vasc Res 1998;35:363-71 (Pubitemid 28503465)
43. Luckhoff A, Pohl U, Mulsch A, Busse R. Differential role of extra-and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br J Pharmacol 1988;95:189-96
44. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14 (Pubitemid 24046692)
45. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-6 (Pubitemid 121001517)
46. Issekutz AC, Rowter D, Springer TA. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J Leukoc Biol 1999;65:117-26 (Pubitemid 29024925)
47. Zang H, Issekutz AC. Growth factor regulation of neutrophil-endothelial cell interactions. J Leukoc Biol 2001;70:225-32 (Pubitemid 32751513)
48. Kadono T, Kikuchi K, Kubo M, et al. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996;35(3 Pt 1):392-7
49. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114
50. Yuge T, Furukawa A, Nakamura K, et al. Metabolism of the intravenously administered recombinant human basic fibroblast growth factor, trafermin, in liver and kidney: degradation implicated in its selective localization to the fenestrated type microvasculatures. Biol Pharm Bull 1997;20:786-93
51. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45 (Pubitemid 27076454)
52. Ma YP, Ma MM, Cheng SM, et al. Intranasal bFGF-induced progenitor cell proliferation and neuroprotection after transient focal cerebral ischemia. Neurosci Lett 2008;437:93-7
53. Finklestein SP, Apostolides PJ, Caday CG, et al. Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds. Brain Res 1988;460:253-9
54. Takami K, Iwane M, Kiyota Y, et al. Increase of basic fibroblast growth factor immunoreactivity and its mRNA level in rat brain following transient forebrain ischemia. Exp Brain Res 1992;90:1-10
55. Anderson KJ, Dam D, Lee S, Cotman CW. Basic fibroblast growth factor prevents death of lesioned cholinergic neurons in vivo. Nature 1988;332:360-1 (Pubitemid 18091076)
56. Akaneya Y, Enokido Y, Takahashi M, Hatanaka H. In vitro model of hypoxia: basic fibroblast growth factor can rescue cultured CNS neurons from oxygen-deprived cell death. J Cereb Blood Flow Metab 1993;13:1029-32 (Pubitemid 23312654)
57. Wagle A, Singh JP. Fibroblast growth factor protect nitric oxide-induced apoptosis in neuronal SHSY-5Y cells. JPET 2000;295:889-95
58. Yamada K, Kinoshita A, Kohmura E, et al. Basic fibroblast growth factor prevents thalamic degeneration after cortical infarction. J Cereb Blood Flow Metab 1991;11:472-8
59. Ren JM, Finklestein SP. Time window of infarct reduction by intravenous basis fibroblast growth factor in focal cerebral ischemia. Eur J Pharmacol 1997;327:11-16 (Pubitemid 27220215)
60. Jiang N, Finklestein SP, Do T, et al. Delayed intravenous administration of basic fibroblast growth factor (bFGF) induces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J Neurol Sci 1996;139:173-9 (Pubitemid 26280883)
61. Bethel A, Kirsch JR, Koehler RC, et al. Intravenous basic fibroblast growth factor decreases brain injury resulting from focal ischemia in cats. Stroke 1997;28:609-15
62. Huang Z, Chen K, Huang PL, et al. bFGF ameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice. Am J Physiol 1997;2722:H1401-5
63. Schabitz WR, Li F, Irie K, et al. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 1999;30:427-32 (Pubitemid 29071813)
64. Kawamata T, Dietrich WD, Schallert T, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc Natl Acad Sci USA 1997;94:8179-84 (Pubitemid 27343797)
65. Kawamata T, Ren JM, Cha JH, Finklestein SP. Intracisternal antisense oligonucleotide to growth associated protein-43 blocks the recovery-promoting effects of basic fibroblast growth factor after acute stroke. Exp Neurol 1999;158:89-96 (Pubitemid 29344320)
66. Wang ZL, Cheng SM, Ma MM, et al. Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia. Neurosci Lett 2008;446:30-5
67. Won SJ, Xie L, Kim SH, et al. Influence of age on the response to fibroblast growth factor-2 treatment in a rat model of stroke. Brain Res 2006;1123:237-44
68. The Fiblast Safety Study Group. Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, FIBLAST) in acute stroke (abstract). Stroke 1998;29:287
69. Clark WM, Schim JD, Kasner SE, Victor S. Trafermin in acute ischemic stroke. Results of a Phase II/III randomized efficacy study (abstract). Neurology 2000;54:A88
70. Bogousslavsky J, Victor SJ, Salinas EO, et al. Fiblast (Trafermin) in acute stroke: results of the European-Australian Phase II/III safety and efficacy. Cerebrovasc Dis 2002;14:239-51 (Pubitemid 36151425)
71. Karapanayiotides T, Bogousslavky J. Neuroprotection: what are its prospects in the stroke patient? Dialogues Cardiovasc Med 2003;8:28-34 (Pubitemid 37484070)
72. Fisher M; for the Stroke Therapy Academic Industry Roundtable: recommendations for advancing development of acute stroke therapies. Stroke therapy academic industry roundtable. Stroke 2003;34:1539-46
73. Shuaib A. Neuroprotection-STAIR-way to the future? Cerebrovasc Dis 2006;22(Suppl 1):10-17
74. Akins PT, Liu PK, Hsu CY. Immediate early gene expression in response to cerebral ischemia. Friend or foe? Stroke 1996;27:1682-7 (Pubitemid 26295925)
75. Tao Y, Black IB, DiCicco-Bloom E. Neurogenesis in neonatal rat brain is regulated by peripheral injection of basic fibroblast growth factor (bFGF). J Comp Neurol 1996;376:653-63 (Pubitemid 27009846)
76. Li Q, Stephenson D. Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat. Exp Neurol 2002;177:531-17
77. Tureyen K, Vemuganti R, Bowen KK, et al. EGF and FGF-2 infusion increases post-ischemic neural progenitor cell proliferation in the adult rat brain. Neurosurgery 2005;57:1254-63
78. Ikeda N, Nonoguchi N, Zhao MZ, et al. Bone marrow stromal cells that enhanced FGF-2 secretion by herpes simplex virus vector improve neurological outcome after transient focal cerebral ischemia in rats. Stroke 2005;36:2725-30
79. Watanabe T, Okuda Y, Nonoguchi N, et al. Postischemic intraventricular administration of FGF-2 expression adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2004;24:1205-13 (Pubitemid 39482481)